Regeneron aflibercept, EYLEA Injection to be featured at ARVO 2023 meeting

Regeneron Pharmaceuticals (REGN) and its collaborator Bayer (BAYRY) announced that aflibercept 8 mg and EYLEA Injection will be featured in 18 presentations at the Association for Research in Vision and Ophthalmology, ARVO, 2023 Annual Meeting from April 23-27. Among the presentations will be new subgroup data and further analyses of aflibercept 8 mg treatment from the pivotal PULSAR and PHOTON trials in wet age-related macular degeneration, wAMD, and diabetic macular edema, DME, as well as the Phase 2 CANDELA trial in wAMD. "Our data presentations at ARVO build on the more than 20 years of industry-leading knowledge and dedicated research aimed at addressing the unmet needs of patients with serious retinal diseases," said Boaz Hirshberg, M.D., Senior Vice President, Clinical Sciences General Medicine at Regeneron. "We look forward to sharing presentations on the efficacy and safety of EYLEA in multiple retinal diseases, as well as additional analyses of the pivotal aflibercept 8 mg trials – all of which reinforce our unwavering commitment to advancing retinal care for patients at risk of losing their vision."